荷CEA-rV的DC增强CD3AK对CEA阳性肿瘤特异杀伤作用的研究

目的 观察荷CEA-rV的DC增强CD3AK细胞对CEA阳性肿瘤细胞的特异性杀伤功能。方法 用脐血制备脐血单个核细胞（UBMC），培养3h后，收集悬浮细胞制备CD3AK，重悬贴壁细胞制备DC。DC培养3d时加入CEA-rV，制备CEA-vV＋DC；在CD3AK培养8d时，加入CEA-rV＋DC混合培养，制备CEA-rV＋DC＋CD3AK。用MTT法测效应细胞UBMC，CD3AK，DC＋CD3AK，CEA-rV＋DC＋CD3AK，分别对CEA阳性靶细胞：LOVO，A549和CEA阴性靶细胞：肝癌细胞株BEL-7402，红白血病细胞株K652的杀伤活性。结果 ①用CEA兔抗人单克隆抗体对四种靶细胞株的鉴定结果表明，LOVO和A549确是CEA阳性细胞株，BEL．7402和K562确是CEA阴性细胞株。②培养10d的DC流式细胞仪检测结果示：高表达MHCI，Ⅱ类分子CD86（82．7％），CD80（51．1％），CD83（57．5％），CD40（69.4％），低表达CD123分子，光学和电子显微镜观察，DC细胞呈不规则形，有大量突起和伪足，成熟DC直径15-20um，胞浆线粒体，内质网丰富。证明为成熟DC。③CD3AK细胞和单纯UBMC细胞的流式细胞仪的免疫分子表型结果是，无论CD3，CD4，CD8和CD28，在CD3AK细胞组中的比率都是UBMC组的二倍以上。说明CD3AK组中成熟T淋巴细胞量明显高于UBMC细胞组。④三种效应细胞CEA-rV＋DC＋CD3AK，DC＋CD3AK和CD3AK对四种靶细胞的杀伤率均比单纯UBMC组明显提高（P〈0.01），而且CEA-rV＋DC＋CD，AK组〉DC＋CD3AK组〉CD3AK组〉UBMC组。说明细胞因子，DC和CEA-rV都有进一步提高UBMC广谱的杀伤肿瘤细胞活性的作用。⑤CEA-rV＋DC＋CD3AK和CD，AK相比较，对CEA阳性细胞LOVO和A549的杀伤活性提高的显著性（P〈0．01）明显优于对CEA阴性细胞K562和BEL-7402显著性（P〈0．05）。说明CEA-rV＋DC能显著提高CD3AK细胞对CEA阳性肿瘤的特异杀伤活性。CEA-rV＋DC＋CD3AK组和DC＋CD3AK组相比，对CEA阴性细胞株的杀伤活性无显著差异（P〉0．05），而对CEA阳性细胞株的杀伤活性确能明显提高（P〈0．01）。进一步证实了CEA-rV能明显提高CD3AK对CEA阳性肿瘤的特异杀伤作用。结论 CEA-rV＋DC能明显提高CD3AK细胞对CEA阳性细胞株杀伤作用，单纯DC对提高CD3AK杀伤CEA阳性细胞的作用不显著，结果表明CEA-rV在提高CD3AK对CEA阳性肿瘤的特异杀伤作用中起着关键作用。     

荷CEA-rV的DC诱导的CIK对CEA阳性原代肿瘤细胞的特异杀伤作用

目的：探讨携带CEA重组基因痘苗病毒（CEA-rV）抗原的树突状细胞（DC）诱导的杀伤细胞（CIK）对CEA阳性原代肿瘤细胞的特异性杀伤作用。方法：用脐血制备脐血单个核细胞（UBMC）、DC、CIK、DC＋CIK、CEArV＋DC＋CIK和CEA-rV＋DC＋UNBC细胞。取新鲜切除的食管癌组织和肺癌组织，制备原代培养的CEA阳性肿瘤细胞作为靶细胞。用MTT法测5组效应细胞对两种靶细胞的杀伤活性。结果：1）用CEA兔抗人单克隆抗体鉴定证实两种原代培养靶细胞系CEA阳性细胞。2）流式细胞仪测定DC的分子表型，证实为DC。3）流式细胞仪测定CIK的CD3^＋CD56^＋双阳性细胞达75．4％。4）DC＋CIK和CIK相比，对两种CEA阳性肿瘤细胞的杀伤率差异无统计学意义，P〉0．05。5）CE-rV4-DC＋CIK对两种CEA阳性肿瘤细胞的杀伤率（78．80％）明显高于DC＋CIK（52．94％），P％0．05。结论：CEA—rV＋DC能明显提高CIK细胞对原代培养的CEA阳性肿瘤细胞的杀伤活性，而单纯DC不能提高CIK的杀伤活性，说明CEA—rV在提高CIK对CEA阳性肿瘤细胞的特异杀伤作用中起重要作用。     

抗原致敏树突状细胞诱导CIK对肺癌细胞杀伤作用的研究

[目的]研究肿瘤抗原致敏的树突状细胞（DC）诱导淋巴因子激活的杀伤细胞（LAK）和细胞因子诱导的杀伤细胞（CIK）对肺癌细胞株A549和肺腺癌原代细胞的杀伤作用。[方法]取健康人外周血单个核细胞,常规诱导出DC、CIK、LAK细胞。用肺癌A549细胞提取的肿瘤抗原冲击DC,倒置显微镜下观察DC形态。流式细胞仪检测DC经抗原冲击和未经抗原冲击后其表型变化。LDH释放法测定杀伤活性。[结果]DC经肿瘤抗原冲击后在镜下呈典型成熟形态,其表面分子CD40、CD80、CD86和HLA-DR的表达明显较未经肿瘤抗原冲击的DC高。DC＋CIK细胞对A549和肺腺癌原代细胞的杀伤活性高于CIK细胞、LAK细胞和DC＋LAK细胞（P〈0.05）,随着效靶比的升高,其杀伤效应随之增强（P〈0.05）。[结论]肿瘤抗原致敏的DC可诱导特异性CIK细胞,DC＋CIK细胞对A549和肺腺癌原代细胞的杀伤作用明显高于DC＋LAK、CIK、LAK细胞。     

树突状细胞对自体CIK细胞体外杀伤肺腺癌细胞影响的研究

目的：研究人外周血树突细胞（dendriticcell,DC）对自体CIK细胞体外杀伤肺腺癌细胞的影响,以期获得具有抗原特异性杀伤功能的细胞毒活性细胞,并分别对CIK、LAK和CD3AK的杀伤效果进行比较.方法：采用某一肺腺癌肿瘤患者外周血单个核细胞（peripheral blood mononuclear cells,PBMNC）,经体外诱导分别扩增出CIK、LAK、CD3AK和DC细胞,再将靶细胞抗原孵育过的DC同三种细胞共同培养,通过镜下动态观察CIK联合DC对癌性胸腔积液中肿瘤细胞的杀伤活性,并利用MTT法检测CIK联合DC体外杀伤人肺腺癌细胞系（SPC-A1）的活性,同时比较CIK、LAK和CD3AK三种细胞的体外杀瘤活性.结果：CIK-ADC的杀伤活性最强为92.3%,明显高于单纯CIK的59.7%和DC-CIK的79.8%,（P值分别为0.025和0.042）,提示CIK A-DC细胞对肿瘤杀伤的特异性.而DC-CIK的杀伤活性为79.8%,也高于单纯CIK对照组59.7%,P=0.034,说明DC具有明显增强CIK细胞杀瘤活性的功能.同时,不论从单纯CIK、LAK、CD3AK细胞毒活性,或是从三种细胞联合DC的细胞毒活性比较,CIK细胞较后两种细胞都具有更强的杀伤活性,P值分别为0.038和0.022.联合DC的自体CIK细胞体外杀瘤活性显著增强,CIK细胞的杀伤活性显著高于LAK、CD3AK两种细胞.结论：DC可明显提高自体CIK细胞的体外杀瘤活性.     

自体来源树突状细胞和细胞因子诱导的杀伤细胞混合培养对原代乳腺癌细胞的杀伤作用

 目的　探讨原代乳腺癌细胞冻融抗原负荷自体来源树突状细胞（DC）与细胞因子诱导的杀伤细胞（CIK）细胞混合培养后对原代乳腺癌细胞杀伤活性的影响作用。方法　取对数生长期的原代乳腺癌细胞制备肿瘤抗原（Ag）,用自体外周血单个核细胞分别制备DC 和CIK细胞;用负荷Ag的DC 和CIK细胞共培养,诱导Ag-DC-CIK细胞。采用流式细胞术检测DC免疫表型,MTT法检测分离的单个核细胞（CBMC）、CIK、Ag-CIK和Ag-DC-CIK对原代乳腺癌细胞的杀伤活性。结果　外周血CBMC、CIK、Ag-CIK和Ag-DC-CIK对乳腺癌原代肿瘤细胞杀伤活性分别是（34.35±3.28）%、（45.91±2.78）%、（50.88±3.22）%、（62.10±5.94）%,实验组细胞（Ag-DC-CIK）对原代乳腺癌细胞的杀伤能力（62.10±5.94）%明显高于对照组（P＜0.01）。结论　肿瘤抗原负荷的DC 能增强CIK细胞对靶细胞的杀伤活性,为DC 的免疫治疗提供了新的思路。     

荷CEA-rV的DC增强CD3AK对CEA阳性肿瘤特异性杀伤作用的研究

Objective： To survey the special killing activity of CD3AK on anti-CEA-positive tumor enhanced by umbilical cord blood dendritic cell （DC） loaded with CEA recombinant vaccinia virus （CEA-rV）. Methods： Freshly isolated umbilical blood mononuclear calls （UBMC） were cultivated for 3 h. Suspension cells and attached calls were used to induce CD3AK calls and DC separately. DC was loaded with CEA-rV on the 3rd day to prepare CEA-rV＋DC. CD3AK cells were co-cultured with CEA- rV＋DC on the 8th day, to prepare CEA-rV＋DC＋CD3AK. The killing activity of each effector＇s cell, which included UBMC, CD3AK, DC＋CD3AK and CEA-rV＋DC＋CD3AK, was measured respectively by MTT reduction assay. Results： （1） 4 target cells were con- firmed by CEA monoclonal antibody of rabbit anti-human. Lovo and A549 were really CEA positive cell lines, while Bel-7402 and K562 were CEA negative cell lines. （2） It was showed by flow-cytometry that the mature DC cultured at 10th day expressed MHC I, II molecules such as CD86, CDS0, CD83 and CD40 highly, but CD123 lowly. The expression rates of CD86, CDS0, CD83 and CD40 was 82.7%, 51.1%, 57.5% and 69.4%, respectively. The appearances and intra-cellular structures of DC were observed through light and electron microscope. The diameter of mature DC was 15-20 μm presented the irregular morphologic appearanca, much prominences and pseudopodium. There were abundant mitochondria and endoplasmic reticulum in DC endochylema. （3） The rates of CD3, CD4, CD8 and CD28 in CD3AK cells group were 2 folds higher than that in UBMC group by FACS. It was said that the numbers of the mature T lymphocyte in CD3AK cells group were much greater than that in UBMC group. （4） The killing activities to 4 target cells of 3 effector＇s cells, which included CEA-rV＋DC＋CD3AK, DC＋CD3AK and CD3AK, were much greater than that of UBMC （P〈0.01）. Moreover, comparing with the killing activities of 4 effector＇s： CEA-rV＋DC＋CD3AK group 〉 DC＋CD3AK group 〉 CD3AK group 〉 UBMC group. It showed that, cytokine, DC and CEA-rV could efficiently elevate the killing activity of UBMC on broad-spectrum tumor cells. （5） Comparing with the killing activities of CEA-rV＋DC＋CD3AK and CD3AK cells to CEA positive and negative cells, the killing activities of CEA-rV＋DC＋CD3AK to CEA positive tumor calls, Lovo and A549 calls （P〈0.01） were remarkably better than that to CEA negative tumor cells BEL-7402 and K562 cells （P〈0.05）. It was said that the CEA-rV＋DC could obviously enhance the killing activity of CD3AK on CEA positive tumor cells. Comparing with the killing activities of CEA-rV＋DC＋CD3AK and DC＋CD3AK cells, the killing activity of CD3AK on CEA negative tumor cells was no statistical difference （P〉0.05）. However, the killing activity to CEA positive cells of CEA-rV＋DC＋CD3AK group was notably higher than that of DC＋CD3AK group. Namely, CEA-rV could distinctly promote the special killing activity to CEA positive tumor cells of CD3AK, but could not do it to CEA negative tumor cells. Conclusion： CEA-rV＋DC could obviously enhance the special killing activity of CD3AK on CEA positive tumor cell lines, while the DC only couldn＇t. The results indicated that the CEA-rV played an important role during the special killing activity of CD3AK cells to CEA positive tumor cells.     

全细胞性肿瘤抗原以不同方式负载树突状细胞诱导肝癌特异性T细胞反应

[目的]研究肝癌3种不同全细胞抗原负载方式（肿瘤细胞裂解物、融合以及肿瘤细胞总RNA）制备DC瘤苗的体外抗肿瘤活性,分析其体外诱导T细胞反应的异同．以期选择更好的DC瘤苗。[方法]分离肝癌患者外周血单核细胞,体外诱导DC;以上述3种抗原负载方式制备DC瘤苗（Lys—DC、Fus—DC、RNA—DC）．刺激肝癌患者淋巴细胞作为效应细胞．肝癌细胞株HepG2为靶细胞,MTT法测定效应细胞对各肿瘤细胞的杀伤作用;分离CD8^＋和CD4^＋ t细胞,瘤苗刺激后,应用IFN-γ ELISA检测试剂盒检测CD8^＋T 细胞IFN-γ分泌．MTT法检测各种瘤苗刺激自体CD4^＋T细胞增殖的能力。[结果]三种瘤苗刺激的淋巴细胞均显示对HepG2高效特异的杀伤活性,但Fus-DC-L、RNA-DC—L对HepG2的杀伤率明显高于Lys—DC—L组：Lys—DC、Fus—DC、RNA—DC刺激的CD8^＋ T细胞组IFN—γ分泌显著高于DC刺激的CD8^＋ T细胞组和单纯CD8^＋ T细胞组;但Fus—DC、RNA—DC刺激组IFN-γ分泌显著高于Lys—DC刺激组：Lys—DC、Fus—DC、RNA—DC组刺激自体CD4^＋ T细胞增殖功能显著高于DC组;但Lys—DC、Fus—DC、RNA—DC刺激自体CD4^＋ T细胞增殖功能无明显差异。[结论]肿瘤总RNA转染的DC以及融合瘤苗能更有效地诱导肿瘤特异性细胞毒性T淋巴细胞反应．是更为有效的DC免疫治疗方式。     

抗原致敏DC诱导CIK细胞对肺腺癌细胞的杀伤作用

[目的]研究肿瘤抗原致敏的树突状细胞（DC）诱导淋巴因子激活的杀伤细胞（LAK）和细胞因子诱导的杀伤细胞（CIK）对肺腺癌原代细胞的杀伤作用，并与单独LAK、CIK细胞的杀伤效果进行比较。[方法]取健康人外周血单个核细胞（PBMNC），常规诱导出DC、CIK、LAK细胞；用肺癌A549细胞提取的肿瘤抗原冲击DC，倒置显微镜下观察DC形态，流式细胞仪检测DC经抗原冲击和未经抗原冲击后其表型变化；把CIK细胞、DC-CIK细胞、LAK细胞和DC-LAK细胞作为效应细胞，肺腺癌原代细胞作为靶细胞，共分为4组，在10：1、20：1、50：1的效靶比时，进行杀伤试验，使用LDH释放法测定杀伤活性。[结果]DC经肿瘤抗原冲击后在镜下呈典型成熟形态；流式细胞仪检测DC经肿瘤抗原冲击和未经肿瘤抗原冲击其表面分子CD40、CD80、CD86和HLA-DR的表达，前者明显高于后者，两者有显著性差异（P〈0．01）；DC—CIK细胞对肺腺癌原代细胞的杀伤活性高于DC—LAK细胞、CIK细胞和LAK细胞（P〈0．05），随着效靶比的升高，DC-CIK细胞对肺癌细胞的杀伤效应随之增强（P〈0．05）。[结论]肿瘤抗原致敏的DC可诱导特异性CIK细胞，DC-CIK细胞对肺腺癌原代细胞的杀伤作用明显高于DC—LAK、CIK、LAK细胞。     

树突状细胞对自体CIK细胞体外杀伤肺腺癌细胞影响的研究

目的:研究人外周血树突细胞(dendriticcell,DC)对自体CIK细胞体外杀伤肺腺癌细胞的影响,以期获得具有抗原特异性杀伤功能的细胞毒活性细胞,并分别对CIK、LAK和CD3AK的杀伤效果进行比较。方法:采用某一肺腺癌肿瘤患者外周血单个核细胞(peripheral blood mononuclear cells,PBMNC),经体外诱导分别扩增出CIK、LAK、CD3AK和DC细胞,再将靶细胞抗原孵育过的DC同三种细胞共同培养,通过镜下动态观察CIK联合DC对癌性胸腔积液中肿瘤细胞的杀伤活性,并利用MTT法检测CIK联合DC体外杀伤人肺腺癌细胞系(SPC-A1)的活性,同时比较CIK、LAK和CD3AK三种细胞的体外杀瘤活性。结果:CIK-A-DC的杀伤活性最强为92.3%,明显高于单纯CIK的59.7%和DC-CIK的79.8%,(P值分别为0.025和0.042),提示CIK-A-DC细胞对肿瘤杀伤的特异性。而DC-CIK的杀伤活性为79.8%,也高于单纯CIK对照组59.7%,P=0.034,说明DC具有明显增强CIK细胞杀瘤活性的功能。同时,不论从单纯CIK、LAK、CD3AK细胞毒活性,或是从三种细胞联合DC的细胞毒活性比较,CIK细胞较后两种细胞都具有更强的杀伤活性,P值分别为0.038和0.022。联合DC的自体CIK细胞体外杀瘤活性显著增强,CIK细胞的杀伤活性显著高于LAK、CD3AK两种细胞。结论:DC可明显提高自体CIK细胞的体外杀瘤活性。     

PHA—CD3AK细胞的体外诱导及其生物学特性初步研究

目的：研究PHA—CD3AK细胞的体外诱导方法及其生物学特性,并与LAK细胞进行比较。方法：分离人外周血单个核细胞（PBMC）,采用植物血凝素（PHA）、单克隆抗体（anti—CD3McAb）和基因重组人白细胞介素2（rhIL-2）、共同诱导制备PHA—CD3AK细胞;应用流式法分析PHA—CD3AK细胞的免疫表型、乳酸脱氢酶法（LDH）检测PHA—CD3AK细胞的杀伤活性,并观察其形态;吉姆萨染色法观察其核型。结果：微量anti—CD3McAb（0．05μg／m1）辅以少量rhIL～2（300U／ml）和PHA（100μg／m1）共同培养,即能诱导和大量扩增PHA—CD3AK细胞,其扩增倍数显著高于LAK细胞,维持高扩增的时间也远较LAK细胞持久;当效靶细胞比为80：1时,PHA—CD3 AK细胞对体外肿瘤细胞（K562）杀伤的百分率为56．5％;免疫表型检测PHA—CD3 AK细胞中CD3^＋、CD4^＋、Cd8^＋细胞的比率分别为（86．5±5．89）％、（38．20±5．27）％、（42．63±3．50）％;核型为正常二倍体,染色体数目为46条。结论：PHA—CD3 AK细胞是以CD3^＋、CD4^＋、CD8^＋细胞为主的异质细胞群,并具有淋巴母细胞样特征,PHA—CD3AK细胞为正常二倍体细胞。PHA—CD3AK细胞是易于体外诱导、扩增能力强,体外存活时间长、杀瘤活性高的一种具有广阔应用前景的肿瘤过继免疫效应细胞。     

APE1表达变化对人非小细胞肺癌细胞A549增殖的影响

目的:探讨脱嘌呤/脱嘧啶核酸内切酶1(apurinic/apyrimidinic endonuclease 1,APE1)对人非小细胞肺癌细胞A549增殖能力的影响,为肺癌的个性化靶向治疗提供理论依据。方法:使用脂质体转染法将重组表达质粒pSIREN-RetroQ-APE1-shRNA和pOZN-HA-APE1导入A549细胞,免疫印迹检测APE1表达情况。MTT、平板克隆实验、免疫印迹检测APE1对非小细胞肺癌细胞增殖的影响,流式细胞仪检测细胞周期的变化。结果:重组载体pSIREN-RetroQ-APE1-shRNA转染细胞后,显著抑制A549细胞中APE1蛋白的表达,与对照组相比,增殖速率明显下降(P＜0.05),平板克隆形成显著减少(P＜0.05),并阻止细胞周期G0/G1期向S期转化,降低CDK2表达。而过表达APE1可增加A549细胞活力,促进细胞增殖,促进细胞周期G0/G1期向S期转化。结论:APE1表达下调对非小细胞肺癌细胞A549生长具有抑制作用,为临床抑制肿瘤生长提供了新的作用靶点。     

Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy

The tumor microenvironment, comprised of tumor cells and tumor-infiltrating immune cells, is closely associated with the clinical outcome of clear cell renal cell carcinoma (ccRCC) patients. However, the landscape of immune infiltration in ccRCC has not been fully elucidated. Herein, we applied multiple computational methods and various datasets to reveal the immune infiltrative landscape of ccRCC patients. The tumor immune infiltration (TII) levels of 525 ccRCC patients using a single-sample gene were examined and further categorized into immune infiltration subgroups. The TII score was characterized by distinct clinical traits and showed a significant divergence based on gender, grade, and stage. A high TII score was associated with the ERBB signaling pathway, the TGF-β signaling pathway, and the MTOR signaling pathway, as well as a better prognosis. Furthermore, patients with high TII scores exhibited greater sensitivity to pazopanib. The low TII score was characterized by a high immune infiltration level of CD8⁺ T cells, T follicular helper cells, and regulatory T cells (Tregs). Moreover, the immune check point genes, including CTLA-4, LAG3, PD-1, and IDO1, presented a high expression level in the low TII score group. Patients in the high TII score group demonstrated significant therapeutic advantages and clinical benefits. The findings in this study have the potential to assist in the strategic design of immunotherapeutic treatments for ccRCC.     

阿霉素诱导粘液表皮样癌细胞凋亡时细胞周期的变化

 在证明10ug／ml阿霉素诱导粘液表皮样癌MEC—1细胞凋亡的基础上，研究细胞凋亡过程中细胞周期变化，以利于临床用药。方法：通过显微镜观察细胞的形态变化和DNA电泳来观察图形，并依靠流式细胞术准确了解用药后细胞周期的变化。结果：光镜下见癌细胞凋亡改变，DNA电泳是典型梯状条图；流式细胞仪测得阿霉素作用5h时，细胞阻于G₂期，24h时细胞阻于G₁期。结论：阿霉素诱导MEC—1细胞凋亡初期，细胞阻于G₂期，后期细胞阻于G₁期。     

RhoB在肾透明细胞癌中的表达及临床意义

目的:探讨RhoB在肾透明细胞癌中的表达及临床意义.方法:采用实时定量PCR、Western blot和免疫组化方法检测RhoB在肾透明细胞癌组织中的表达情况.选取60例肾透明细胞癌组织标本,详细收集病人临床病理资料,通过免疫组化方法检测RhoB在肾透明细胞癌组织中的蛋白表达水平,并分析RhoB的蛋白水平与临床病理资料的关系.结果:与对应瘤旁肾组织相比,RhoB的mRNA及蛋白表达水平在肾透明细胞癌组织标本中明显降低;RhoB的蛋白表达水平在不同年龄、性别组间差异无统计学意义(P>0.05),而在肿瘤直径大小、T分期、临床分期和组织分级间差异有显著统计学差异(P<0.05).结论:RhoB的表达降低可能在肾透明细胞癌的肿瘤发生中发挥作用,且其表达下降可能与肾透明细胞癌的恶性进展有关.     

Pygopus2的表达下调抑制肺癌细胞的增殖能力

目的:探讨肺癌细胞中Pygopus2（Pygo2）的表达及意义。方法:Western Blot明确肺癌细胞系中Pygo 2的表达后,应用 siRNA、MTT、流式细胞术等方法检测及其表达对肺癌细胞增殖凋亡能力的影响。结果:肺癌细胞系中存在Pygo2的过表达,其表达下调能够通过阻滞细胞周期及促进细胞凋亡,进而抑制肺癌细胞的增殖能力。结论:Pygo2的异常表达是导致肺癌发生发展的重要因素。     

VEGF-C在宫颈癌细胞中的表达及与细胞增殖的关系

目的:研究VEGF-C在宫颈癌细胞中的表达及其对宫颈癌细胞增殖的影响。方法:采用反义技术,脂质体介导VEGF-C反义寡核苷酸转染人宫颈癌Hela细胞。应用荧光定量RT-PCR法、间接免疫荧光标记法,检测转染后细胞内VEGF-C在mRNA、蛋白水平的变化。MTT比色法检测细胞生长的变化。结果:脂质体介导VEGF-C反义寡核苷酸,转染宫颈癌Hela细胞的转染效率大于90％。转染了反义寡核苷酸的反义组VEGF-C在mRNA和蛋白水平上,较未转染组和正义组均明显下降（P<0.05）。MTT法检测转染了VEGF-C反义寡核苷酸的细胞,明显看到反义组细胞的生长受到明显抑制。结论:VEGF-C可影响人宫颈癌Hela细胞增殖,本实验通过抑制VEGF-C,进而可阻断宫颈癌的淋巴转移,为实现靶向性基因治疗的可行性,提供了实验依据。     

Radiation sensitivity of merkel cell carcinoma cell lines

: Merkel cell carcinoma (MCC), being a small cell carcinoma, would be expected to be sensitive to radiation. Clinical analysis of patients at our center, especially those with macroscopic disease, would suggest the response is quite variable. We have recently established a number of MCC cell lines from patients prior to radiotherapy, and for the first time are in a position to determine their sensitivity under controlled conditions.     

Lupeol及其衍生/修饰物对肝癌细胞增殖影响的研究

目的：探讨lupeol及其结构改造后衍生/修饰物对肝癌细胞HepG2和SMMC7721细胞增殖的作用。方法：对lupeol进行化学结构修饰,然后应用MTT方法检测lupeol及其衍生/修饰物对HepG2和SMMC7721细胞增殖的作用。结果：MTT数据显示,lupeol及其衍生/修饰物均能抑制HepG2和SMMC7721细胞增殖,并且具有浓度依赖性。Lupeol、H1、T1和T2的IC50分别为40μmol/L-50μmol/L、约120μmol/L、约50μmol/L和70μmol/L-80μmol/L。结论：lupeol结构改造后,并没有提高其对肝细胞肝癌细胞增殖的抑制作用。     

非小细胞肺癌细胞分泌蛋白谱的鉴定

目的筛选非小细胞肺癌潜在的早期诊断标志物，对非小细胞肺癌细胞系A549的分泌蛋白进行鉴定。方法收集A549细胞培养上清中的蛋白进行蛋白双向电泳，应用基质辅助激光解析电离飞行时间质谱（MALDI—TOF—MS）及生物信息学鉴定A549凝胶上特有的蛋白质点。结果鉴定出人属的蛋白质点17个，包括α肌动蛋白，γ肌动蛋白，α烯醇酶（ENO1），锰-超氧化物歧化酶（MnSOD），谷胱甘肽S转移酶P（GSTP1—1），Dihydrodiol dehydrogenase 2（DDH），磷酸甘油酸变位酶1（PGAM1），葡萄糖依赖性胰岛素释放肽受体（GIPR），肽基脯氨基顺反异构酶（PPIA），磷脂酰乙醇胺结合蛋白（PEBP），蛋白基因产物9．5（PGP9．5），Peroxiredoxin1（PDX1），Galectin-1及专利蛋白WO0222660等。结论该研究为非小细胞肺癌早期诊断标志物的筛选提供了新的方法和候选分子。     

Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma

We present the case of a 62-year-old Japanese man whose histological diagnosis was adenoendocrine cell carcinoma of the gallbladder at autopsy, but whose antemortem diagnosis was squamous cell carcinoma. The patient was admitted to hospital with complaints of occasional vomiting and abdominal pain. Abdominal computed tomography revealed a large tumor on the gallbladder involving the adjacent liver, colon, and duodenum, with multiple metastases in the greater omentum and paraportal lymph nodes. The serum level of squamous cell carcinoma antigen (SCCA) was high, whereas that of carbohydrate antigen (CA) 19-9, as well as that of carcinoembryonic antigen (CEA) was within the normal range. Due to these clinical features, we first suspected advanced squamous cell carcinoma of the gallbladder. After two cycles of gemcitabine monotherapy, the tumor had become enlarged and the regimen was changed to a combination of docetaxel and cisplatin. Though tumor regression was achieved and his serum SCCA level normalized after 3 months, the patient rejected additional chemotherapy and died 8 months after the diagnosis. The histopathological findings made by autopsy demonstrated the tumor to be an adenoendocrine cell carcinoma without squamous carcinoma cells. The case is interesting in that the clinical features were similar to those of squamous cell carcinoma of the gallbladder.